Melatonina
Anno: 1997
-
Riferimento:Support Care Cancer. 1997 Mar;5(2):126-9.Azione della melatonina:Concomitant administration of MLT during chemo-therapy may prevent some chemotherapy-induced side-effects,Target:Influence of MLT on chemotherapy toxicity.
Anno: 1998
-
Titolo: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cellsRiferimento:Cancer Res. 1998 Oct 1;58(19):4383-90.Azione della melatonina:Pretreatment of MCF-7 cells with 1 nM melatonin increased the response of tumoral cells to the antiinvasive effects.Target:Anti-invasive actions.
-
Riferimento:Epidemiology. 1998 Sep;9(5):490-4.Azione della melatonina:Blind people have a lower cancer incidence, although other explanations than the higher melatonin exposure must also be considered.Target:Totally blind people.
-
Riferimento:Proc Soc Exp Biol Med. 1998 Nov;219(2):144-8.Azione della melatonina:DHEA or MLT supplementation restored the average speed; ambulatory time and distance traveled of retrovirus infected mice.Target:LP-BM5 retrovirus infection.
-
Riferimento:Lancet. 1998 Aug 22;352(9128):626.Azione della melatonina:No abstract available.Target:No abstract available.
-
Titolo: Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factorsRiferimento:Mol Cell Endocrinol. 1998 Jun 25;141(1-2):53-64.Azione della melatonina:Melatonin and EGF transactivate the ER, making the ER refractory to activation by estradiol.Target:Estrogen receptor (ER), epidermal growth factor (EGF).
-
Riferimento:Menopause. 1998 Spring;5(1):60-4. Review.Azione della melatonina:Melatonin might be implicated in menopause-associated processes such as breast cancer.Target:Melatonin replacement therapy.
-
Riferimento:Int J Biol Markers. 1998 Jul-Sep;13(3):154-7.Azione della melatonina:Studies evaluating circadian DHEAS secretion in relation in that of the pineal hormone MLT.Target:Dehydroepiandrosteronesulfate (DHEAS).
-
Riferimento:Br J Cancer. 1998 Jun;77(12):2129-37.Azione della melatonina:Melatonin (10(-9) M)and atRA (10(-9) M) should be considered for preclinical and clinical evaluation against ER-positive human breast cancer.Target:Oestrogen receptor (ER), all-trans retinoic acid (atRA).
-
Riferimento:Mol Carcinog. 1998 Mar;21(3):149-55. Review.Azione della melatonina:Reduction of melatonin levels by EMFs can caused inactivation of melatonin receptors which may cause cancer.Target:Electromagnetic fields (EMFs).